PELL Bio-Med Technology Co. Ltd. (6949.TW)
TWD 117.0
(0.86%)
TWD 117.0
(0.86%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 385.1 Million TWD | 75.17% |
| 2022 | 193.81 Million TWD | 20.06% |
| 2021 | 161.43 Million TWD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 102.56 Million TWD | 46.44% |
| 2024 Q1 | 74.1 Million TWD | -25.76% |
| 2023 Q3 | 110.05 Million TWD | 4.67% |
| 2023 Q1 | 47.14 Million TWD | -22.06% |
| 2023 Q2 | 105.14 Million TWD | 123.0% |
| 2023 FY | 339.49 Million TWD | 75.17% |
| 2023 Q4 | 99.82 Million TWD | -9.3% |
| 2022 Q4 | 60.49 Million TWD | -6.74% |
| 2022 FY | 193.81 Million TWD | 20.06% |
| 2022 Q3 | 64.86 Million TWD | 0.0% |
| 2021 FY | 161.43 Million TWD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Apex Biotechnology Corp. | 389.4 Million TWD | 1.103% |
| Sinphar Pharmaceutical Co.,Ltd. | 807.86 Million TWD | 52.331% |
| Panion & Bf Biotech Inc. | 817.56 Million TWD | 52.896% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 437.58 Million TWD | 11.992% |
| GenMont Biotech Incorporation | 204.2 Million TWD | -88.589% |
| Abnova (Taiwan) Corporation | 126.72 Million TWD | -203.901% |
| Adimmune Corporation | 1.13 Billion TWD | 66.031% |
| Tanvex BioPharma, Inc. | 2.16 Billion TWD | 82.175% |
| Polaris Group | -3.06 Million TWD | 12664.633% |
| Energenesis Biomedical CO.,LTD. | 267.06 Million TWD | -44.2% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -2051.791% |